Redefining bone infection treatment with advanced nanotechnology
‘Inborn’ designs Injectable Bone gels for Regenerative Nanomedicine. Its Nanoparticle-Based Gel (NBG) offers an advanced therapy for local, and intracellular delivery of antibacterial agents for treatment of recurrent bone infectionsN
New Consortium Project Launched: REBORN Targets Medication-Related Jawbone Necrosis
Inborn B.V. is proud to announce its participation in REBORN (Regenerative Engineering for Bone-treatment Optimization and Recovery after Necrosis), a 24-month public-private collaborative initiative alongside Radboudumc and HAN University of Applied Sciences (Hogeschool van Arnhem en Nijmegen), supported within the ORANGE Health consortium framework.
Addressing an Unmet Clinical Need
Widely prescribed bone-strengthening therapies—essential for managing osteoporosis and oncological conditions—carry a severe, debilitating side effect: medication-related osteonecrosis of the jaw (MRONJ). In the Netherlands alone, tens of thousands of patients taking these medications are at risk, with the condition impacting up to 15% of high-risk oncology cohorts. The resulting chronic infections and exposed bone frequently necessitate invasive surgical resections and prolonged care, imposing a heavy burden on patient quality of life and the healthcare system.
Dual-Action Biomaterial Technology
The REBORN project sets out to validate a minimally invasive alternative utilizing Inborn’s biomimetic, bone-like gel technology. The formulation delivers a targeted dual mechanism:
-
Osteoconductive Scaffolding: Serves as a localized matrix that actively guides endogenous cells to rebuild healthy, vascularized bone architecture.
-
Targeted Therapeutic Delivery: Directly eradicates deep-seated microbial infections at the defect site, minimizing systemic exposure and side effects.
Preclinical Validation & Regulatory Dossier
Over the next 24 months, the consortium partners will rigorously test the gel’s safety and regenerative performance in preclinical models that closely mirror human jaw anatomy. As part of the broader ORANGE Health mission to accelerate impactful biomedical innovations from bench to bedside
What is Osteomyelitis?
1 in 5 mortality risk without prompt treatment
Osteomyelitis is a progressive inflammatory disease resulting in bone destruction. It has increasing prevalence, represents a major financial burden for health systems and affects the quality of life of the patients and their families
ABOUT US
Pioneering solutions: From lab to patient care
Born from a vision at Regenerative Biomaterials group, Inborn BioMedical was co-founded by entrepreneurs committed to translating advanced research into impactful solutions for patients. Our NBG harnesses cutting-edge nanotechnology to deliver effective, safe, and long-lasting antibiotic therapy, addressing the unique challenges of bone infections. Driven by this goal, Inborn BioMedical bridges the gap between innovative science and real-world medical needs.
Our technology
Inborn’s Nanoparticle-Based Gel (NBG) is a paste-like gel engineered with hydroxyapatite and gelatin nanoparticles, designed to combat Osteomyelitis effectively. Our gel can be applied directly to the infection site, minimizing systemic side effects and enabling a controlled release of antibiotics.
Patented methodologies in nanoparticle preparation
Spherical hydroxyapatite nanparticles
Proprietary preparation method for Spherical Hydroxyapatite (sHA) nanoparticles
Spherical gelatin nanoparticles
Proprietary preparation method for Spherical Gelatin (sGel) nanoparticles
“Prosthetic joint infections are a devastating complication after primary and revision arthroplasty operations. Traditional treatment methods require multiple surgeries and long-term antibiotic regimens with high morbidity and mortality, placing a significant burden on patients and the healthcare system.”
Dr. Wim Rijnen, MD
Orthopaedic surgeon, Radboudumc
“Inborn’s nanoparticle-based gel is cyto- and biocompatible, and its therapeutic efficacy has been convincingly confirmed in preclinical studies. Consequently, this novel gel creates a beneficial environment for cell infiltration, migration, and tissue remodeling. Moreover, its capacity for intracellular delivery of antibacterial agents is unique and offers new opportunities for the design of novel biomaterials with superior antibacterial efficacy."
Prof. Sander Leeuwenburgh
Regenerative Biomaterials, Radboudumc
QUESTIONS?
Whether you’re curious about our technology, Osteomyelitis, potential devliery options or even collaborations, we’re here to answer any questions.